Introduction
============

Secreted frizzled-related proteins (sFRPs) are palmitoylated secreted glycoproteins that are involved in cell proliferation and neoplastic growth ([@b1-etm-05-02-0475],[@b2-etm-05-02-0475]). sFRPs consist of ∼300 amino acids and are composed of a cysteine-rich domain (CRD) at their amino terminal ends with 30--50% homology to the active site of the Frizzled receptor ([@b3-etm-05-02-0475],[@b4-etm-05-02-0475]). The CRD of Frizzled serves as the active site for Wnt binding and subsequent signal transduction. This class of CRD is conserved in diverse proteins, including the seven-transmembrane class of tyrosine receptor kinases of the receptor tyrosine kinase-like orphan receptor (ROR) family ([@b5-etm-05-02-0475]). sFRPs act as extracellular signaling ligands and are able to downregulate Wnt signaling by forming an inhibiting complex with the Frizzled receptors ([@b6-etm-05-02-0475]). Since Wnt causes cancer cells to grow, it was originally hypothesized that sFRPs are inhibitors of cancer cell growth ([@b7-etm-05-02-0475]) but a subsequent study revealed that sFRP-3 (also known as FrzB) is present at high levels in metastatic renal cancer tissues ([@b8-etm-05-02-0475]). This study also demonstrated that sFRP-3 promotes invasion by renal cancer cells ([@b8-etm-05-02-0475]). sFRPs have been linked to tumor-promoting activities in other types of cancer ([@b9-etm-05-02-0475]). The elevated levels of sFRP-3 in various types of cancer suggest that it may be a valuable therapeutic target ([@b7-etm-05-02-0475]).

Four endogenous cardiac hormones \[vessel dilator, kaliuretic peptide (KP), atrial natriuretic peptide (ANP) and long-acting natriuretic peptide (LANP)\] have anticancer effects *in vivo*([@b10-etm-05-02-0475]--[@b12-etm-05-02-0475]), and *in vitro* have been reported to decrease the numbers of human renal carcinoma cells by up to 81% ([@b13-etm-05-02-0475]), human colorectal cancer cells by 89--97% ([@b14-etm-05-02-0475]) and pancreatic cancer cells by up to 65% ([@b15-etm-05-02-0475]). The present investigation was designed to determine whether the four cardiac hormones inhibit sFRP-3 in human renal carcinoma, human pancreatic cancer and human colorectal cancer cells as part of their anti-cancer mechanism(s) of action. The results showed that each of the four cardiac hormones potently inhibited sFRP-3 in the three different types of cancer.

Materials and methods
=====================

Cardiac hormones
----------------

The four cardiac hormones were obtained from Phoenix Pharmaceuticals, Inc. (Belmont, CA, USA).

Human colorectal, pancreatic and renal cancer cells
---------------------------------------------------

Human colorectal cancer (ATCC number CCL-225), pancreatic carcinoma (ATCC number CRL-1469, panc-1) and renal adenocarcinoma (CRL-1611) cells were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). The ATCC authenticated these cell lines and performed the genotype and phenotype evaluations, including DNA profiles (STR) and cytogenetic analyses.

Culturing of human colorectal adenocarcinoma cells
--------------------------------------------------

The propagation of the human colorectal adenocarcinoma cells was performed in Roswell Park Memorial Institute (RPMI)-1640 medium with 2 mM glutamine adjusted with the addition of 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES, 1 mM 90% sodium pyruvate and 10% fetal bovine serum (FBS; Sigma Chemical Co., St. Louis, MO, USA) at a temperature of 37°C with 5% CO~2~ as recommended by the ATCC. Cells were dispensed into new flasks with sub-culturing every 6--8 days. The growth medium was changed every three days.

Culturing of human pancreatic carcinoma cells
---------------------------------------------

The propagation of the human pancreatic carcinoma cells was carried out in Dulbecco's modified Eagle's plus Ham's F12A 1:1 mixture containing 1.2 g/l sodium bicarbonate (Sigma Chemical Co.) supplemented with 15 mM HEPES and FBS 10% with 5% CO~2~ at a temperature of 37°C, as recommended by the ATCC. Cells were dispensed into new flasks with subculturing every 6--8 days. The growth medium was changed every 3 days.

Culturing of human renal adenocarcinoma cells
---------------------------------------------

The propagation of the human renal cell adenocarcinoma cells was carried out in Eagle's Minimum Essential Medium supplemented with 2 mM glutamine adjusted by the addition of 1.5 g/l sodium bicarbonate, 1 mM 90% sodium pyruvate and 10% FBS (Sigma Chemical Co.) with 5% CO~2~ at a temperature of 37°C, as recommended by the ATCC. Cells were dispensed into new flasks with subculturing every 6--8 days. The growth medium was changed every 3 days.

sFRP-3 ELISA
------------

Analysis of sFRP-3 was carried out using the DuoSet sFRP-3 immunoassay (R&D Systems, Inc., Minneapolis, MN, USA), a 6-hour solid phase ELISA designed to measure sFRP-3 levels in cell culture. In this assay, an immobilized capture antibody specific for sFRP-3 binds to sFRP-3 using a standard streptavidin conjugated to horseradish peroxidase. This ELISA specifically recognizes sFRP-3 without cross-reactivity or interference with FRP-1, FRP-4 and sFRP-2. The sFRP-3 ELISA was calibrated against a highly purified NSO-expressed recombinant human sFRP-3 (R&D Systems, Inc). The standard curve for this assay was calculated using a four-parameter logistic (4-PL) curve fit.

sFRP-3 research protocol
------------------------

The human colorectal cancer, pancreatic carcinoma and renal adenocarcinoma cells were subcultured for 24 h, then ∼5,000 cells of each line in 50 μl of their respective media were seeded in 96-well plates with 50 μl media containing 10 μM, 1 μM, 100 nM, 10 nM, 1 nM and 100 pM concentrations of each of the four cardiac hormones separately (i.e. six concentrations of four cardiac hormones measured six times at each concentration; n=6 for each concentration). Standards from R&D Systems were diluted using Reagent Diluent and added to blank wells to serve as reference points of known sFRP-3 concentrations. In this assay, absorbance was examined at a 540 nm wavelength using a 96-well Gen5, Synergy Mx microplate reader (BioTek, Winooski, VT, USA) set according to the parameters recommended by the manufacturer. There were 32 controls for each cell line (n=32) and six experimental determinations for each of the six concentrations of the four cardiac hormones in the three cancer cell lines (n=6).

Statistical analysis
--------------------

Data are expressed as the means ± SEM. The statistical analyses of the data were performed using a Student's t-test for unpaired values. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Inhibition of sFRP-3 in human colorectal cancer cells
-----------------------------------------------------

An 83% (P\<0.0001) reduction of the sFRP-3 level was observed in the human colorectal cancer cells following treatment with 100 nM vessel dilator ([Fig. 1](#f1-etm-05-02-0475){ref-type="fig"}). KP and ANP caused maximal reductions of the sFRP-3 level in the human colorectal cancer cells of 83% and 84% respectively, both at a concentration of 100 nM (P\<0.0001), while LANP caused a maximal decrease of 83% (P\<0.0001) at a concentration of 10 μM ([Fig. 1](#f1-etm-05-02-0475){ref-type="fig"}). In the human colorectal cancer cells, each of the cardiac hormones caused a similar significant (P\<0.0001) decrease in the sFRP-3 level.

Inhibition of sFRP-3 in human pancreatic carcinoma cells
--------------------------------------------------------

Vessel dilator maximally reduced the sFRP-3 level by 77% (P\<0.0001) in the human pancreatic cancer cells at its 1 nM concentration ([Fig. 2](#f2-etm-05-02-0475){ref-type="fig"}). KP and ANP also maximally reduced the sFRP-3 level in the human pancreatic cancer cells by 77% (P\<0.0001), the former at a concentration of 100 pM and the latter at concentrations of 100 nM and 1 nM ([Fig. 2](#f2-etm-05-02-0475){ref-type="fig"}). LANP reduced the sFRP-3 level in the human pancreatic cancer cells by 78% at its 1 nM concentration (P\<0.0001; [Fig. 2](#f2-etm-05-02-0475){ref-type="fig"}). Each of the cardiac hormones had a similar marked ability to reduce the sFRP-3 level in the human pancreatic cancer cells.

Inhibition of sFRP-3 in human renal adenocarcinoma cells
--------------------------------------------------------

Vessel dilator decreased the sFRP-3 level in the human renal cancer cells by 68% at a concentration of 1 μM (P\<0.0001), and KP maximally reduced the sFRP-3 level by 66% (P\<0.0001) at the same concentration. The maximal decrease in the sFRP-3 level of the human renal cancer cells following treatment with ANP was 68% (P\<0.0001) at a concentration of 10 nM and following treatment with LANP was 66% (P\<0.0001) at a concentration of 100 nM ([Fig. 3](#f3-etm-05-02-0475){ref-type="fig"}). In the human renal cancer cells, the abilities of each of the cardiac hormones to inhibit human sFRP were not significantly different as each caused similar significant decreases in the sFRP-3 level. The four cardiac hormones caused similar marked decreases in the sFRP-3 levels of the human colorectal, pancreatic and renal cancer cells ([Figs. 1](#f1-etm-05-02-0475){ref-type="fig"}--[3](#f3-etm-05-02-0475){ref-type="fig"}).

Discussion
==========

It has been reported that sFRP-3 promotes renal cancer growth when injected into nude mice ([@b8-etm-05-02-0475]). sFRPs have also been linked to tumor promotion in other types of cancer ([@b9-etm-05-02-0475]). It has been suggested ([@b7-etm-05-02-0475]) that the elevated sFRPs in various types of cancers may be valuable therapeutic targets. The present investigation demonstrates that vessel dilator, KP, ANP and LANP decreased the levels of sFRP-3 by 77--78% in human pancreatic cancer cells, 83--84% in human colorectal cancer cells and 66--68% in human renal cancer cells. These significant reductions of sFRP-3 suggest that it is a target of the four cardiac hormones in a variety of types of cancer. With respect to the mechanism by which the reduction of sFRP-3 levels by the cardiac hormones leads to their anticancer effects, the ability to inhibit sFRP-3, the active CRD of the Frizzled receptor ([@b3-etm-05-02-0475]), blocks the propagation of the signal responsible for causing cancer cell growth.

It is important to note that the reductions in sFRP-3 levels (up to 84%) are similar in magnitude to the 80% elimination of human pancreatic cancers in mice and 86% elimination of human small-cell lung cancers growing in mice ([@b10-etm-05-02-0475],[@b11-etm-05-02-0475]). The decrease in FRP-3 is also similar in magnitude (% decrease) in cell number of cancer cells *in vitro*([@b13-etm-05-02-0475]--[@b15-etm-05-02-0475]). These observations suggests that sFRP-3 is an important therapeutic target of the cardiac hormones in mediating their anticancer effects ([@b9-etm-05-02-0475]--[@b11-etm-05-02-0475]). Furthermore, this target is present in more than one cancer type, and the present study demonstrates that sFRP-3 is a treatment target in human pancreatic, renal and colorectal cancers for each of the four agents evaluated.
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![Vessel dilator (VDL), kaliuretic peptide (KP), atrial natriuretic peptide (ANP) and long-acting natriuretic peptide (LANP) maximally reduced the level of secreted frizzled-related protein 3 (sFRP-3) (in pg/ml) in human colorectal cancer cells by 83%, 83%, 84% and 83%, respectively. Each of these reductions was significant at P\<0.0001 when evaluated by the Student's t-test for unpaired values. Each bar represents the mean ± SEM of 32 determinations for the control and 6 determinations for the experimental groups.](ETM-05-02-0475-g00){#f1-etm-05-02-0475}

![Secreted frizzled-related protein 3 (sFRP-3) in human pancreatic cancer cells was maximally reduced by 77%, 77%, 77% and 78% by vessel dilator (VDL), kaliuretic peptide (KP), atrial natriuretic peptide (ANP) and long-acting natriuretic peptide (LANP), respectively. Each of these reductions was significant at P\<0.0001 when evaluated by the Student's t-test for unpaired values. Each bar represents the mean ± SEM of 32 determinations for the control and 6 determinations for the experimental groups.](ETM-05-02-0475-g01){#f2-etm-05-02-0475}

![The level of secreted frizzled-related protein 3 (sFRP-3) in human renal adenocarcinoma cells was maximally reduced by 68%, 66%, 68% and 66%, by vessel dilator (VDL), kaliuretic peptide (KP), atrial natriuretic peptide (ANP) and long-acting natriuretic peptide (LANP), respectively. Each of these reductions was significant at P\<0.0001 when evaluated by the Student's t-test for unpaired values. Each bar represents the mean ± SEM of 32 determinations for the control and 6 determinations for the experimental groups.](ETM-05-02-0475-g02){#f3-etm-05-02-0475}
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